Clinical Trials Logo

WHIM Syndrome clinical trials

View clinical trials related to WHIM Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03995108 Active, not recruiting - WHIM Syndrome Clinical Trials

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Start date: October 24, 2019
Phase: Phase 3
Study type: Interventional

This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with WHIM syndrome. Participants are allowed to continue treatment in the Open-Label Period, if regionally applicable, until mavorixafor becomes commercially available, or until the study is terminated by the Sponsor.